Iron Dyshomeostasis and Mitochondrial Function in the Failing Heart: A Review of the Literature.

Autor:	Mousavi-Aghdas, Seyed Ali, Farashi, Ebrahim, Naderi, Nasim
Předmět:	THERAPEUTIC use of iron IRON metabolism HEART failure risk factors ADENOSINE triphosphate CARDIOVASCULAR diseases risk factors PYRIDINE IN vitro studies INTRAVENOUS therapy MYOCARDIUM HEART cells CHELATION therapy IN vivo studies IRON IRON in the body MITOCHONDRIA CREATINE OXIDATIVE stress RISK assessment IRON deficiency QUALITY of life IRON overload HEART failure LIPID peroxidation (Biology) DISEASE complications
Zdroj:	American Journal of Cardiovascular Drugs; Jan2024, Vol. 24 Issue 1, p19-37, 19p
Abstrakt:	Cardiac contraction and relaxation require a substantial amount of energy provided by the mitochondria. The failing heart is adenosine triphosphate (ATP)- and creatine-depleted. Studies have found iron is involved in almost every aspect of mitochondrial function, and previous studies have shown myocardial iron deficiency in heart failure (HF). Many clinicians advocated intravenous iron repletion for HF patients meeting the conventional criteria for systemic iron deficiency. While clinical trials showed improved quality of life, iron repletion failed to significantly impact survival or significant cardiovascular adverse events. There is evidence that in HF, labile iron is trapped inside the mitochondria causing oxidative stress and lipid peroxidation. There is also compelling preclinical evidence demonstrating the detrimental effects of both iron overload and depletion on cardiomyocyte function. We reviewed the mechanisms governing myocardial and mitochondrial iron content. Mitochondrial dynamics (i.e., fusion, fission, mitophagy) and the role of iron were also investigated. Ferroptosis, as an important regulated cell death mechanism involved in cardiomyocyte loss, was reviewed along with agents used to manipulate it. The membrane stability and iron content of mitochondria can be altered by many agents. Some studies are showing promising improvement in the cardiomyocyte function after iron chelation by deferiprone; however, whether the in vitro and in vivo findings will be reflected on on clinical grounds is still unclear. Finally, we briefly reviewed the clinical trials on intravenous iron repletion. There is a need for more well-simulated animal studies to shed light on the safety and efficacy of chelation agents and pave the road for clinical studies. [ABSTRACT FROM AUTHOR]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu Full text from SpringerLink